Who are XZP-3287+ Letrozole/Anastrozole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abemaciclib + Aromatase Inhibitor, Ultra-Long GnRH Agonists + Letrozole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xzp-3287-letrozole-anastrozole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

XZP-3287+ Letrozole/Anastrozole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

XZP-3287+ Letrozole/Anastrozole (XZP-3287+ Letrozole/Anastrozole) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor combination. Area: Oncology.

phase 3 Aromatase inhibitor combination Oncology Small molecule Live · refreshed every 30 min

Target snapshot

XZP-3287+ Letrozole/Anastrozole (XZP-3287+ Letrozole/Anastrozole) — Xuanzhu Biopharmaceutical Co., Ltd.. XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
XZP-3287+ Letrozole/Anastrozole TARGET	XZP-3287+ Letrozole/Anastrozole	Xuanzhu Biopharmaceutical Co., Ltd.	phase 3	Aromatase inhibitor combination
Abemaciclib + Aromatase Inhibitor	Abemaciclib + Aromatase Inhibitor	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + Aromatase inhibitor combination	CDK4/6 + Aromatase
Ultra-Long GnRH Agonists + Letrozole	Ultra-Long GnRH Agonists + Letrozole	University of Palermo	marketed	GnRH agonist + aromatase inhibitor combination	GnRH receptor; aromatase (CYP19A1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor combination class)

Xuanzhu Biopharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). XZP-3287+ Letrozole/Anastrozole — Competitive Intelligence Brief. https://druglandscape.com/ci/xzp-3287-letrozole-anastrozole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab